A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether patients with high-risk myelodysplastic
syndromes (MDS) treated with azacitidine have improved survival compared to conventional care
treatments. The study will also assess the effect of treatments on response, duration of
response, and transformation to acute myeloid leukemia (AML). The study will continue for 12
months following last patient enrolled.
See study AZA PH GL 2003 CL 001 E for information about the extension to this study.